ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
RegulatoryapprovedTivicay PDPositive
AI Analysis
Summary
ViiV Healthcare's Tivicay PD received FDA approval for use in paediatric HIV-1 patients weighing at least 2 kg when used with other antiretroviral agents. This represents a regulatory approval for an expanded paediatric population.
Outcome Details
FDA approval for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg
Importance:8/10
Sentiment:
0.80
FDA approvalpaediatric indicationHIV therapyregulatory
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 27, 2026 8:42 AM